A Prospective, Multi-Center, Double-Blinded, Placebo-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With the BioSTAR Septal Repair Implant to Reduce Refractory Migraine Headache With Aura.
试验速览
- 阶段
- 2 期
- 发起方
- NMT Medical
- 入组人数
- 610
- 试验地点
- 4
- 主要终点
- Efficacy: Migraine reduction rates during analysis period.
研究概览
简要总结
The objective of the study is to investigate the safety and effectiveness of PFO closure with the BioSTAR Septal Repair Implant System in a population of patients that have refractory migraine (with aura) and who have failed medications.
详细描述
During the last five years, transcatheter and surgical closure of PFO in the cyrptogenic stroke and TIA population has grown in frequency world-wide. Observational retrospective reports, from both single and multi-center experiences of over 400 patients, suggest Patent Foramen Ovale (PFO) closure to reduce the risk of recurrent migraine events in these populations may be beneficial, particularly for those patients in the migraine with aura subgroup. Although none of these reports are from prospective, randomized, controlled trials, the reports are compelling enough in their totality to support further investigation of a well defined group in a prospective manner. The patients reported in these studies were brought to PFO closure with no expectation of their procedure having any impact on their migraine. In fact, in many cases, the discovery of a history of migraine was not made until well after the PFO closure procedure.
This clinical trial will prospectively compare the safety and effectiveness of PFO closure with the BioSTAR device to a control arm. Patients will be followed one year post-implant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age between 18 and
- •migraine history prior to age 50
- •must meet definition of refractory migraine with aura
- •must have a Patent Foramen Ovale (PFO) within bubble study specifications.
- •must provide informed consent. Guardian consent is not accepted.
- •patient's heart structure and vasculature must be compatible with BioSTAR Septal Repair Implant System.
- •patient must not be pregnant and agrees not to become pregnant during study participation
排除标准
- •Medical conditions or medications that are not compatible with protocol or that would increase the patient's risk.
- •patient must not have any cardiac or vascular anomalies, repaired or not, that would be incompatible with the delivery system or device for PFO occlusion.
- •Currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current trial endpoints.
结局指标
主要结局
Efficacy: Migraine reduction rates during analysis period.
Safety: Incidence of Major Adverse Cardiac Events (MACE) one year post-implantation.
次要结局
- Efficacy:Change in number of attacks from baseline period compared to analysis phase.
- Safety: Device success during index procedure without procedural complication.
- Incidence of major AEs during index procedure and post-procedure as they relate to the device and protocol specified medications.